BRAF and melanoma: To investigate whether this latter compound may exert inhibiting effects on a wider range of BRAF mutants (similarly to those previously reported with vemurafenib/PLX4720 [5,7]), melanoma cell lines carrying the two remaining most prevalent BRAF mutations (V600D and V600R) were here treated with dabrafenib and cellular proliferation was then assessed.